IDEAYA Biosciences Darovasertib Combo Advances Uveal Melanoma Care
South San Francisco, California, USA, April 21, 2026 In a significant advancement in precision oncology, IDEAYA Biosciences, Inc. has...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
South San Francisco, California, USA, April 21, 2026 In a significant advancement in precision oncology, IDEAYA Biosciences, Inc. has...
South San Francisco, California | April 10, 2026 IDEAYA Biosciences has announced that it will disclose topline results from...
